Balance Sheet

Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Biocryst Pharmaceuticals (BCRX) Amortization of Deferred Charges (2023)

Biocryst Pharmaceuticals' Amortization of Deferred Charges history spans 6 years, with the latest figure at $8.1 million for Q4 2023.

For Q4 2023, Amortization of Deferred Charges changed N/A year-over-year to $8.1 million; the TTM value through Dec 2023 reached $8.5 million, changed N/A, while the annual FY2023 figure was $8.5 million, N/A changed from the prior year.
Amortization of Deferred Charges reached $8.1 million in Q4 2023 per BCRX's latest filing, up from $110000.0 in the prior quarter.
In the past five years, Amortization of Deferred Charges ranged from a high of $8.1 million in Q4 2023 to a low of $8.1 million in Q4 2023.